William Blair analyst Andrew Brackmann has reiterated their bullish stance on NEO stock, giving a Buy rating on April 1.
Andrew Brackmann has given his Buy rating due to a combination of factors that suggest NeoGenomics is poised for significant long-term growth. The recent investor meetings, which included key figures such as the new CEO Tony Zook, highlighted the company’s undervalued potential in terms of growth and profitability. Despite a recent decline in share prices following a surprise CEO change and a slight revenue miss, these events are seen as a strategic entry point for investors.
Brackmann’s confidence is bolstered by the new leadership under Zook, who has a strong track record in commercial leadership and product launches. The company’s transition from a turnaround phase to a growth-focused strategy, with new product launches and potential partnerships or acquisitions, supports this positive outlook. Furthermore, the updated guidance under Zook emphasizes meeting expectations rather than exceeding them, aligning with a more predictable growth trajectory. This strategic shift, combined with the current valuation, presents a compelling case for the stock’s potential upward movement over the next 12 to 24 months.